Back to Authors

Villasboas, José C.

https://orcid.org/0000-0002-2907-0809

A5037629427 | I1330342723

Mayo Clinic

Citations 209

Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience

Leukemia & Lymphoma | November 30, 2023 | Volume: 65 | Issue: 3 | Pages: 389-393

10.1080/10428194.2023.2285236 | PMID 38031734

1423 Novel immunotherapy based on commensal-derived peptides to drive an effective CD8 T Cell response against selected tumor-associated antigens (TAAs)

Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A1582-A1582

10.1136/jitc-2023-sitc2023.1423

191 Expediting MxIF panel development in FFPE for the PhenoCycler platform: the ‘Joker’ panel development kit

Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A217-A218

10.1136/jitc-2023-sitc2023.0191

P1215: CHARACTERIZATION AND CLINICAL SIGNIFICANCE OF T FOLLICULAR HELPER SUBSETS IN FOLLICULAR LYMPHOMA

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e5464225

10.1097/01.hs9.0000971756.54642.25

P1359: TUMOR-SPECIFIC, T-CELL-TARGETING MICRORNA IS ASSOCIATED WITH CART CELL FAILURE IN B CELL MALIGNANCIES

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e07303db

10.1097/01.hs9.0000972324.07303.db

P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e214536e

10.1097/01.hs9.0000971228.21453.6e

Final Result of DIAL (NCI10089), Randomized Phase 2 trial of Varlilumab combined with Nivolumab in patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 592-594

10.1002/hon.3164_444

Characterization of the tumor microenvironment in classic Hodgkin lymphoma: determining the deep immunophenotypic signature of T cells using mass cytometry

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 266-267

10.1002/hon.3164_179

The Immunobiology of histologic transformation in follicular lymphoma: a multi‐omic case‐control study

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 261-262

10.1002/hon.3164_174

ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 121-122

10.1002/hon.3163_82